Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 12:22
Please select the service you want to use:
Smartlinks | FCC - Federal Communications Commission | News | Crime and Judiciary | Laws and Regulation Documents | Politics and Policy | Policy and Regulation | Government | National Government | Economy | Laws and Regulation Documents | Telecommunications Services | Arts and Culture | Entertainment | Media | Radio and Television | Policy and Regulation Authorities
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact